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Algorithmic Fusion of Gene Expression Profiling for
Diffuse Large B-Cell Lymphoma Outcome Prediction
Qiuming Zhu, Senior Member, IEEE, Hongmei Cui, Kajia Cao, and Wing C. Chan
Abstract—Many different methods and techniques have been
investigated for the processing and analysis of microarray gene
expression profiling datasets. It is noted that the accuracy and
reliability of the results are often dependent on the measure-
ment approaches applied, and no single measurement so far is
guaranteed to generate a satisfactory result. In this paper, an
algorithmic fusion approach is presented for extracting genes that
are predictive to clinical outcomes (survival–fatal) of diffuse large
B-cell lymphoma on a set of microarray data for gene expression
profiling. The approach integrates a set of measurements from
different aspects in terms of the discrepancy indications and
merit expectations of the gene expression patterns with respect
to the clinical outcomes. A combination of statistical and non-
statistical criteria, continuous and discrete parameterizations, as
well as model-based and modeless evaluations is applied in the
approach. By integrating these measurements, a set of genes
that are indicative to the clinical outcomes are better captured
from the gene expression profiling dataset.
Index Terms—Algorithmic fusion, cross-projection (CP), dis-
crete partition (DP), Fisher’s discrimination, gene expression
profiling, outcome prediction.
I. INTRODUCTION
DNA MICROARRAY technology provides biologists withthe ability to measure the expression levels of thousands
of genes simultaneously in a single experiment. It is essential 
to have some effective means to extract the biologically signifi-
cant information from the large amount of microarray datasets. 
Identifying genes that are predictive to certain clinical outcomes 
is one of the important goals in the analysis of gene expression 
profiling data from tumor specimens [1].
Two gene expression profiling studies of diffuse large B-cell 
lymphoma (DLBCL) had been undertaken by researchers 
to identify genes predictive to clinical outcomes [16], [17]. 
Rosenwald et al. identified the functional (gene expression 
signature) groups of 17 genes that are predictive to survival 
from a dataset of over 7394 genes on 154 clinical cases using 
statistics-based evaluations. They found that the groups of 
genes are closely associated with the genes that divide the 
tumor into distinct biologic subtypes [16]. Shipp et al. applied 
a supervised learning method on an expression profiling 
dataset of 7139 genes on 58 tumor specimens, and identified 
13 genes that are highly predictive to the outcomes [17].
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The research presented in this paper uses Shipp’s dataset
(www.genome.wi.mit.edu/MPR/lymphoma) and complements
Shipp’s outcome predictors with our results based on a multi-
measurements algorithmic fusion approach.
There are a number of methods discussed in the literature
for identifying genes that are indicators of certain diseases or
health disorders. General approaches include 1) parametric
methods, such as the principal component analysis [13], inde-
pendent component analysis, and separation correlation metric
(SCM), alternatively known as the Fisher’s discrimination
criterion (FDC) [7]; and 2) nonparametric methods, such as
the projection pursuit regression (PPR) [9], support vector
machines [4], neural networks, threshold number of misclassi-
fication (TNoM) [3], and expectation maximization [6]. Most
methods resulted in certain scoring of individual genes for the
objective-relevance detection.
The parametric methods use a set of statistical metrics derived
from the gene expression profiling under the assumption of cer-
tain probability distribution models. Statistical methods are usu-
ally reliable and accurate in large data set analysis, especially for
the methods that apply the class of robust statistics [10]. How-
ever, the incongruence between the relatively small number of
data samples collected in current practice and the high dimen-
sions of the genes profiles often makes the statistical model hard
to be justified, one version of the so-called dimension curse in
scientific computation. Moreover, the statistical measurements
are easily biased or distorted by the uncertainty and inaccuracy
of the sample labels, the exact category of the specimen, and
irregularity of the sample distributions.
The nonparametric methods do not rely on the assumption
of statistical models and parameters. Rather, they work directly
toward the objectives, such as discrimination or prediction,
by applying certain nonstatistical metrics on the data sam-
ples. These methods are advantageous at constraining and
attenuating the effects of smaller sample numbers. However,
the diversity of measurement metrics and the uncertainty,
including the imprecision and incompleteness of the data set,
of the individual data samples often make it hard to obtain
consistent results in different experimentations. That is, the
results are easily affected by the experimental situation and
environmental conditions. The inherent variability of the cases
from the clinical/pathologic diagnoses also affects the feature
identification. For example, the survival data in the DLBCL
cases are not only determined by the genomic alterations in the
tumor, or the treatment applied, but also by the diverse types
of individual circumstances such as the patient’s age, general
health conditions, and specific drug metabolism. This type of
inherent variability affects both parametric and nonparametric
approaches.
It is known that measurement of some attributes of a set of ob-
jects is the process of assigning numbers or other symbols to the
objects in such a way that the relationships of the objects being
measured [2], [18]. A particular way of assigning numbers or
symbols according to the attributes of the objects is called a scale
of measurement [5]. These kinds of problems are the subject of
study in measurement theory. Measurement theory shows that
strong assumptions are required for certain statistics to provide
meaningful information about reality of the object in concern.
Often the only thing for sure is that the measurement is a mono-
tone increasing function of valuation. In many cases, people
would like to choose an analysis that yields invariant results.
The study of such invariants is a major concern of measure-
ment theory. However, measurement theory does not provide a
complete solution to such problem. In particular, measurement
theory does not take random measurement error into account,
and if such errors are an important aspect of the measurement
process, then additional analysis methods are called for.
It is intuitive to imagine that a better result could be obtained
in general by combining a number of the measurements together
[19]. However, the quality of the result relies on how the dif-
ferent measurements are integrated and what is the set of the
measurements that form a good combination of measurement
for a given set of data and measurement objectives. While a
selected set of measurements might be monotonic increasing,
some of them are in continuous values and some are in dis-
crete scales. Moreover, some of the measurements are in statis-
tical nature and some are nonparametric, and some of them are
model-based and some are modeless as well. These factors pose
various kinds of difficulties for the measurement combinations.
In this paper, we present an algorithmic fusion method that is
based on an integration of a set of parametric and nonparametric
measurements in different scoring/ranking metrics. The method
extracts a group of genes that are predictive to the DLBCL clin-
ical outcome by integrating the measurements in a crossover
ranking-and-selection process. In the following, the major an-
alytic methods used in the algorithmic fusion approach will be
presented in Section II. Section III describes the algorithm for
fusing the multiple measurements to generate a unified set of
predictive genes. The results obtained from applying the ap-
proach to the sample DLBCL data set for outcome prediction are
presented in Section IV. Section V presents concluding remarks.
II. MULTIPLE MEASUREMENTS
The basic idea of measurement theory is that a quantitative
scale is a mapping between some objects and a given set of asso-
ciated numerical values. This mapping, however, is not arbitrary
but is supposed to meet some requirements. It is important to
be mindful of certain measurement procedures and to recognize
fully their strengths and shortcomings [5]. In gene expression
profiling, different algorithms and evaluation techniques often
result in a different set of candidate genes that are extracted for
outcome predictions. It is, therefore, desirable to have a set of
criteria established in the analysis so as to control the gene se-
lecting process, and to properly assess the merit of the resulting
gene sets from the measurements. We adopted the “distinctive-
ness” and “representativeness” as our major criteria in this re-
search. That is, the technique discussed in this paper is aimed at
extracting the gene set that are as much “distinctive” as possible
with respect to different outcome classes so that the distributions
of the gene values are well separated, that is, the gene expres-
sion levels are numerically distinguishable. These kinds of sets
of genes are often called predictors. In the following, we discuss
some typical measurement methods that address their special
characteristics for revealing the gene expression discrepancies
with respect to different clinical outcomes in terms of the above
criteria.
A. SCM/FDC as a Class Separation Metric
The SCM, also known as the FDC [7], is a well-known and
popular parametric method for identifying data attributes and
their projections that are most likely separable among different
classes. It has been used in several applications for extracting
genes that are differentially expressed diseases or with different
clinical outcomes [4]. However, it is also known that the FDC
is not an absolute criterion for yielding accurate classifications
[20]. The method should be combined with other correlation
analyses in practical applications to diminish some parametric
side effects.
Let and be the labels of two different sample classes,
for example, the surviving versus fatal cases of the DLBCL. The
one-dimensional (1-D) SCM/FDC method aims at maximizing
the criterion
where , , is the mean value of the 1-D projection
of the data samples of classes in a direction expressed by
a vector , respectively. That is, ,
where represents the gene expression vector
which consists of expression values of the individual gene over
all clinical samples. The is the number of data samples in
class . The , , is
the variance for the projected samples of class in direction ,
respectively. is a vector in the space
that serves as a transformation operator on which the samples
are projected to a 1-D space .
is called the between class scatter matrix, where ,
, is the mean vector of the data samples of classes in
the original vector space of . is called the
within-class scatter matrix, where , , is the covariance
matrix of the data samples of classes in the space of .
When limiting the projection vector to the form of
that is, the axes of the Euclidean
coordinates, the 1-D SCM/FDC represents a measurement
of individual gene according to its mean and variance pa-
rameters with respect to the original class designations. Let
denote such a measurement on gene , i.e, on vector
, the SCM/FDC criterion (denoted as FDC
simply) can be expressed as
where the and are the th gene expression values of the
th sample corresponding to classes and , respectively.
Fig. 1. FDC measurement of the DLBCL dataset. (a) Genes of top 50 FDC ranks. (b) FDC values of top 200 genes.
The FDC values provide a means for ranking the separability
of the genes with respect to the tumor outcome classes. Our
experimental result of the FDC measurements on the DLBCL
dataset is illustrated in Fig. 1, where Fig. 1(a) presents the genes
ranked at the top 50 in the FDC measurement and Fig. 1(b)
shows the FDC values of the top 200 genes. The top bar with
color green and black in Fig. 1(a) indicates the sample cases
in survival and fatal outcomes, respectively. From Fig. 1, we
can see that the FDC measurement does not provide an overall
good indication of the genes that are related to the survival–fatal
outcomes. A number of genes even ranked at the top ten of rel-
atively high FDC values do not show a clear pattern of separa-
tion for the samples in two different outcomes. That is, not every
gene with the high FDC value is distinctive toward the separa-
tion of two distinct outcome classes.
B. Cross-Projection (CP) Index as a Maximum Likelihood
Measurement
The generic term “projection pursuit” refers to two statistical
procedures: exploratory projection pursuit and PPR. Friedman
and Tukey coined the term projection pursuit for a technique of
finding interesting low-dimensional projections of high-dimen-
sional data set [9]. Since then, projection pursuit has been a gen-
eral method for exploratory data analysis. Fridman also charac-
terized a given projection by a numerical index that can then be
used as a basis of a heuristic search to locate the “interesting”
projections [8]. A projection pursuit index concerns with asso-
ciating a functional value to each and every low-dimensional
projection that reveal the most details about the structure of the
data set [11]. Once an interesting set of projections has been
found, the existing structures (e.g., a set of genes, data clusters,
etc.) of different patterns can be extracted and analyzed sepa-
rately by the indexes [15]. Usually this index value is derived
from an evaluation function associated with the projection. The
function itself is called the projection indexing and is usually
differentiable to facilitate efficient optimization [12]. A search is
usually conducted for revealing correlative projections by max-
imizing the index over the projection space, that is all possible
projections of the function.
To identify genes that are predictive of surviving and fatal
DLBCL tumor cases in terms of maximizing the likelihood of
classification, we applied the projection pursuit method to the
gene expression profiles. Our method projects the gene expres-
sion values of individual case sample to the corresponding like-
lihood function with respect to the distribution of the whole
class. We call it a CP. The quantitative measurements of the pro-
jections over all cases are accumulated to form the index. As the
projections take place between different pairs of gene patterns
or class spaces, a number of genes reflecting the characteristics
of the gene expressions among different classes are extracted
according to the scoring of the projection indexing values.
A CP process and the computation of the cross-projection
index (CPI) take the following steps in general.
1) Considering two data sets and , where
and
Data points , are case
samples from a class .
Data points , are case
samples from a class .
Each point , is a vector
, where is the number of data
attributes (genes in our experiments) in each case sample.
2) Assuming that the elements of the data point are in
Gaussian distributions
where , and
, ; and is
the number of data points in class .
3) A CP of , the th element of data point of class ,
to the distribution of class is defined as
Similarly, we have the CP of , the th element of
data point of class , to the distribution of class
4) Taking a logarithm transformation of the above expres-
sions, we have
These measurements are the likelihood of the sample
vectors with respect to different outcome classes under
inspection.
5) The CPI is computed as follows:
Let
be the number of data points on gene such
that , and
be the number of data points on gene such
that .
A CPI of gene is defined as
A graphical display of the expression profiles for 50 genes
with high CPI values in the DLBCL dataset is shown in Fig. 2(a).
The CPI values of the top 200 genes are shown in Fig. 2(b). Note
that the CPI measurements are discrete. It is a scoring of the
maximum likelihood of a data point with respect to a class
. A continuously valued CPI can also be defined such that
it takes the count of accumulative differences of the likelihood
values on the CPs. It yields the similar results as the CPI defined
above.
C. DP (Discrete Partition) Index as a Minimum
Misclassification Measurement
While the FDC and CPI are parametric methods for data
evaluation, we applied a nonparametric and discrete method
for a measurement of the minimum misclassification (error)
rate on the data set. The technique is based on the principle
of the TNoM [3]. The TNoM approach tries to find a data
point on a gene expression profile over all test cases such
that the total misclassified samples would be minimized if the
data point is taken as a separation threshold to divide the
gene expression values into two distinct classes. The minimum
number of samples misclassified at a best point is called the
Fig. 2. (a) Genes of top 50 CPI ranks. (b) CPI values of top 200 genes.
DP index (DPI). The process of DPI computation is described
as follows.
For each gene its expression values
over all test samples are on the row of
the data set
1) Sort the expression values of row
in ascending order;
2) Begin Loop:
k 1;
V[k] the th sample-value in the sorted
list (from left to right);
A[k] number of class samples at the
left of V[k] number of class
samples at the right of the V[k];
B[k] number of class samples at the
left of V[k] number of class
samples at the right of the V[k];
K++;
End of Loop;
3) DPI [j]=the smallest value from A[k]
and B[k];
End of procedure.
The algorithm works in the following fashion: 1) the values
in A[k] and B[k] are the possible number of misclassifications
while applying V[k] as a threshold value; 2) the value DPI[j] is
the minimum number of misclassifications for gene ; and 3)
the genes are scored with the best possible nonmisclassifications
(minimum misclassification) when the algorithm terminates.
Note that the genes are not uniquely ranked in DPI because
multiple genes can have the same DPI value, that is, scored
the same. In this case, we give the same ranking value to
these genes. That is, these genes will be ranked the same.
Fig. 3(a) shows a graphical display of the expression profiles
for the top 50 genes with high DPI values in the DLBCL
dataset. The DPI values of the top 200 genes are shown in
Fig. 4(b).
Fig. 3. (a) Genes of top 50 DPI ranks. (b) DPI values of top 200 genes.
Fig. 4. Algorithmic fusion of the gene expression measurements.
D. Discussions of the Multiple Measurements
The three genes evaluation approaches, namely 1) the FDC
measurement, 2) the CPI, and 3) the DPI, address different
aspects of the gene evaluation criteria discussed at the begin-
ning of this section. A comparison of the main characteristics
of these approaches is shown in Table I.
Our experiment results show that the FDC, CPI, and DPI
measurements do not correlate to each other on the given
data set. On the other hand, genes with consistently higher
ranks in all FDC, CPI, and DPI measurements do show a
distinctive pattern for separating the two outcome classes. This
means that by certain ways of combining the measurements,
it is possible to select a set of genes that possess an overall
better performance than the sets extracted from each individual
measurement. Table II lists the FDC, CPI, and DPI values
of four typical genes in our experiment. A column at right
also indicates whether the gene is in the final selection of
predictive set after applying the algorithmic fusion process to
the measurements. However, the combination cannot be done
by a simple application of majority voting scheme. An additive
property does not hold among these measurements either. A
more subtle procedural approach, thus, is needed to take count
of the different measurement types and scales of the above
and to come up with an integrated list of resulting genes.
TABLE I
NATURE OF THE MEASUREMENT OF THE THREE ALGORITHMS
TABLE II
FDC, CPI, AND DPI MEASUREMENTS OF A SELECTIVE SET OF GENES
III. ALGORITHMIC FUSION
In this section, we describe a fusion algorithm applied to the
above three principal measurements for the extraction of genes
that are indicative to the DLBCL clinical outcomes. Methods
of combining multiple measurements and classifiers have been
studied and applied successfully in solving a number of pat-
tern recognition problems such as the handwritten character
recognitions [14], [19]. Most of them dealt with classifiers
that result in similar measurements or the measurements are
valued in the similar nature of representations. The main fea-
ture of the fusion algorithm applied in this research is that it
addresses the problem of combining multiple measurements
that are in different scales and conjugative spaces of numeric
values. Note that it is very likely that each gene is valued
differently in the FDC measurement because of the continuity
nature of the measurement. The genes, thus, can be individu-
ally ranked in the FDC measurement. However, a number of
genes in the CPI and DPI measurements would be valued the
same, therefore, they cannot be individually ranked according
to these measurements. For example, the genes U70663 and
U83908 (Table II) both have a CPI value 40, so they are both
ranked at a CPI level of 36. The fusion algorithm, thus, is
necessary to have a way of taking care of these cases and
integrating the data that bear different ranking schemes.
A fusion algorithm called G_FUSION, which stands for
algorithmic fusion of gene expression profiling measurements,
is developed and applied in our research. The G-FUSION em-
ploys a parallel crossover integration technique conducted on
the results of the two parametric measurement, FDC and CPI,
and the one nonparametric measurement, DPI. The linkage of
procedures is illustrated in the diagram shown in Fig. 4.
Let FDCL, CPIL, and DPIL denote three gene lists formed
from the FDC, CPI, and DPI measurements, respectively. Note
that genes in FDCL are ranked individually, while in the CPIL
and DPIL, there could be multiple genes occupying the same
ranking node/slot of the list. That is, each node of the CPIL or
DPIL represents a set of genes at the same CPI or DPI level.
Thus, the number of nodes in the FDCL is equal to the number of
genes, while the number of nodes in the CPIL or DPIL is equal
to the number of different CPI or DPI measurement levels. We
also give a numeric value to each node of CPIL
and DPIL to record the number of genes that have the ranks fall
ahead of and up to the level of the CPI or DPI measurement
The G_FUSION is a best-first rank-preserving data fusion
algorithm. It means that during the fusion process, the genes
with the best evaluation values in both measurements are always
extracted first, and the genes in the resulting list are still ranked
according to their ranks in the orders of the original lists. The
fusion process runs in two steps: First, the FDCL and the CPIL
are fused to generate a list FDC/CPI-L. In the second step, the
FDC/CPI-L is fused with the DPIL, which results a final list of
genes where the more indicative genes to the clinical outcomes
are placed near the top of the list.
The fusion algorithm is presented as follows.
G_FUSION procedure: Lists Crossover (take
the crossover of FDCL and CPIL as example)
Input:
1) List FDCL where genes are sorted
according to the FDC measurements
in descending order.
2) List CPIL where genes are sorted
according to the CPI in descending
order.
Output: A new list FDC/CPI-L where
genes are sorted by FDC values after
crossover operations on the lists FDCL
and CPIL.
Computation steps:
1) Let be a prespecified constant
indicating the number of genes to
be selected.
2) Initialize the list FDC/CPI-L to
empty.
3) Let be a variable initialized to
the top-most level of CPI;
TABLE III
GENES EXTRACTED FROM THE ALGORITHMIC FUSION (SORTED IN CPI)
4) While the number of genes in
FDC/CPI-L is less than , do
a) For each gene such that
has the CPI value less than
or equal to in CPIL, AND
is NOT in the FDC/CPI-L list
yet; if is present in the
top number of genes
in FDCL, place in the list
FDC/CPI-L.
b) Increase the to the next
level of the CPIL.
5) Sorting the genes in FDC/CPI-L ac-
cording to their FDC values.
Note that the number of genes finally selected in the
FDC/CPI-L may be greater than , because there are multiple
genes at the same rank in the CPIL. Once the rank is
reached, all genes that have the CPI value equal to are
selected with respect to their position in FDCL, which is done
in step 4(a).
The same procedure is applied for a crossover fusion of the
lists FDC/CPI-L and DPIL. To ensure that the second fusion
step extracts sufficient number of genes , the first fusion
step should have a relatively large value. On the other hand,
of course, we can always come back to the first fusion step to
get more genes if the second fusion step does not generate the
desired number of genes. This adaptation process is not difficult
to implement on the base of the G-FUSION algorithm.
IV. EXPERIMENTAL RESULTS
The DLBL data sets used in our experiment contains
58 patient cases with 7139 genes evaluated for each case
(www.genome.wi.mit.edu/MPR/lymphoma). To create an
outcome predictor that integrates a number of highly predictive
genes, we focused on evaluating individual genes to identify
those genes that are highly predictive. The results we obtained
after applying the algorithmic fusion to the total genes and
Fig. 5. Plot of gene expression values of the 13 genes extracted by the
algorithmic fusion.
cases are listed in Table III. By a selection of parameters of
in the second fusion procedure, a set of 13 genes with
the measurements , , and
were extracted.
Using the algorithmic fusion approach, four genes in our se-
lected set overlap with the result in Shipp’s paper [17]. They are
6206 PRKACB gene (protein kinase C-beta-2);
6873 TRANSDUCIN-LIKE ENHANCER PROTEIN 1;
1394 PDE4B Phosphodiesterase 4B, cAMP-specific;
3861 Nuclear antigen H731 mRNA.
A graphical display of the gene expression values of the 13
genes in our selection is shown in Fig. 5. The mean and variance
values of the genes in the predictor set based on the expression
values of the original dataset are shown in Table IV.
To verify the results, we applied a simple linear discriminate
function (without considering the distribution variance and as-
suming equal probability for both survival and fatal cases) to
the DLBCL gene expression profiling dataset. The test yields
a total of 46 (27 19) cases correctly identified. That is, one
additional case was correctly assigned in our experiment com-
pared with Shipp’s 13 genes reported [17] (see Table V). The
linear classifier (predictor) takes a form of the following:
where is a normalized vector that con-
tains the 15 genes of the extracted gene set. The and
are the mean vectors of with respect to the two classes (sur-
vival–fatal), respectively.
TABLE IV
MEAN AND VARIANCE VALUES OF THE 13 GENES EXTRACTED FROM THE ALGORITHMIC FUSION
TABLE V
CLASSIFICATION TESTS ON THE EXTRACTED GENE SET
Applying a quadratic discriminate function (with considera-
tion of the distribution variance parameters and assuming equal
probability for both survival and fatal cases) defined on the ex-
tracted genes to the DLBCL gene expression profiling dataset
yields a total of 48 (30 18) cases correctly identified. That is,
three additional cases were correctly assigned compared with
Shipp’s report. The quadratic classifier (predictor) takes a form
of the following:
which can be written as
where
,
, and
.
The and are the covariance matrices of with respect
to the two classes (survival–fatal), respectively.
Note that it is not always true that the gene expression values
are independent to each other. That is, there are some genes
such that their expression values with respect to certain clinical
aspect, such as the survival–fatal outcome, are correlated. The
genes can tend to be coactivated in response to a given stim-
ulus and, therefore, cannot guarantee to be expressed indepen-
dently of one another. The implication of this correlation means
that some of the genes in the set extracted in our experimenta-
tion may be correlated. Measurement theory suggests that the
relationships among items are logically connected to the rela-
tionships of items to the latent variable. Therefore, additional
analysis and gene pattern classification processes performed on
different clinical aspects of the genes are needed to detect and
identify the correlations (or irrelevance) of these genes. How-
ever, this does not exclude us to use the extracted set of genes as
the outcome predictors. There are other technical aspects con-
cerning the types of measurements and the uniqueness of the
measurements, in relation to the general measurement theory
that address the dependency problem and need to be further
studied.
V. CONCLUSION
We have presented a multifaceted measurement integration
approach for identification of genes predictive to patient’s sur-
vival outcomes in the analysis of a DLBCL expression profiling
dataset. A main feature of the approach is that it combines the
measurements in both parametric and nonparametric domains,
as well as continuous and discrete natures. The algorithmic
fusion attempts to attenuate the effects of measurement un-
certainties coherent in the dataset by proper association of the
multifaceted measurements. However, we must point out that
our results were purely based on numeric evaluations of the
gene expression profiles. No considerations of the biological
nature of the genes are taken; that is, the functionalities of
the genes are not considered in the selection process. More-
over, these measurements provide the relative importance, in
terms of the discrepancies of the expression values between
cases of different classes (survival–fatal), of the genes with
respect to the others. Since we limited the selection to 13
genes, it is inevitable that some important genes, many of
which are possibly biologically meaningful, may be missed
in our results. We are sure that the gene list can be further
expanded with an adjustment of the selection parameters, such
as the value of the fusion algorithm. We also believe that
our method can be applied to many other data sets analyses
tasks, including the gene expression profiles for other clinical
diagnosis assistances.
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